The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily
A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes
- Luigi Meneghini, MD1⇑,
- Stephen L. Atkin, MD2,
- Stephen C.L. Gough, MD3,
- Itamar Raz, MD4,
- Lawrence Blonde, MD5,
- Marina Shestakova, MD6,
- Stephen Bain, MD7,
- Thue Johansen, MD8,
- Kamilla Begtrup, MSC8,
- Kåre I. Birkeland, MD9,
- on behalf of the NN1250-3668 (BEGIN FLEX) Trial Investigators*
- 1University of Miami Miller School of Medicine, Miami, Florida
- 2Michael White Diabetes Centre, Hull York Medical School, Hull, U.K.
- 3Oxford Centre for Diabetes, Endocrinology, and Metabolism, and NIHR Oxford Biomedical Research Centre, Churchill Hospital, Oxford, U.K.
- 4Diabetes Unit, Hadassah-Hebrew University Hospital, Jerusalem, Israel
- 5Ochsner Diabetes Research Unit, Department of Endocrinology, Ochsner Medical Center, New Orleans, Louisiana
- 6Endocrinology Research Center, Moscow, Russian Federation
- 7Abertawe Bro Morgannwg University Health Board, Singleton Hospital, Swansea, U.K.
- 8Novo Nordisk A/S, Søborg, Denmark
- 9Department of Endocrinology, Oslo University Hospital, and Faculty of Medicine, University of Oslo, Oslo, Norway
- Corresponding author: Luigi Meneghini, .
OBJECTIVE The requirement to inject current basal insulin analogs at a fixed time each day may complicate adherence and compromise glycemic control. This trial evaluated the efficacy and safety of varying the daily injection time of insulin degludec (IDeg), an ultra-long-acting basal insulin.
RESEARCH DESIGN AND METHODS This 26-week, open-label, treat-to-target trial enrolled adults (≥18 years) with type 2 diabetes who were either insulin naïve and receiving oral antidiabetic drugs (OADs) (HbA1c = 7–11%) or previously on basal insulin ± OAD(s) (HbA1c = 7–10%). Participants were randomized to 1) once-daily (OD) IDeg in a prespecified dosing schedule, creating 8–40-h intervals between injections (IDeg OD Flex; n = 229); 2) once-daily IDeg at the main evening meal (IDeg OD; n = 228); or 3) once-daily insulin glargine at the same time each day (IGlar OD; n = 230). The primary outcome was noninferiority of IDeg OD Flex to IGlar OD in HbA1c reduction after 26 weeks.
RESULTS After 26 weeks, IDeg OD Flex, IDeg OD, and IGlar OD improved HbA1c by 1.28, 1.07, and 1.26% points, respectively (estimated treatment difference [IDeg OD Flex − IGlar OD]: 0.04% points [–0.12 to 0.20], confirming noninferiority). No statistically significant differences in overall or nocturnal hypoglycemia were found between IDeg OD Flex and IGlar OD. Comparable glycemic control and rates of hypoglycemia were seen with IDeg OD Flex and IDeg OD. Adverse event profiles were similar across groups.
CONCLUSIONS The use of extreme dosing intervals of 8–40 h demonstrates that the daily injection time of IDeg can be varied without compromising glycemic control or safety.
This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-1668/-/DC1.
↵*A complete list of the BEGIN FLEX principal investigators is provided in Supplementary Table 11.
- Received August 17, 2012.
- Accepted December 18, 2012.
- © 2013 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.